

=> d his

(FILE 'HOME' ENTERED AT 09:08:20 ON 10 NOV 2004)

L1 FILE 'HCAPLUS' ENTERED AT 09:08:33 ON 10 NOV 2004
1 (US20040047848 OR US20020192190)/PN

FILE 'REGISTRY' ENTERED AT 09:09:45 ON 10 NOV 2004

L2 FILE 'HCAPLUS' ENTERED AT 09:09:47 ON 10 NOV 2004
TRA L1 1- RN : 1 TERM

L3 FILE 'REGISTRY' ENTERED AT 09:09:48 ON 10 NOV 2004
1 SEA L2

L4 FILE 'WPIX' ENTERED AT 09:09:58 ON 10 NOV 2004
1 (US20040047848 OR US20020192190)/PN

=> b hcap

FILE 'HCAPLUS' ENTERED AT 09:10:37 ON 10 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Nov 2004 VOL 141 ISS 20
FILE LAST UPDATED: 9 Nov 2004 (20041109/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 11

L1 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:377879 HCAPLUS
DN 126:342451
ED Entered STN: 18 Jun 1997
TI Induction of immunological tolerance by habituation of host animals to foreign tissues for organ transplantation
IN Latta, Paul P.
PA Latta, Paul P., USA
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61F002-02
ICS A61K009-107; A61K035-12; A61K035-39
CC 15-8 (Immunochemistry)
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|--------------|
| PI | WO 9715243 | A1 | 19970501 | WO 1996-US17234 | 19961025 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG | | | | |
| | AU 9674795 | A1 | 19970515 | AU 1996-74795 | 19961025 |
| | EP 955948 | A1 | 19991117 | EP 1996-937029 | 19961025 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | US 2002192190 | A1 | 20021219 | US 1999-226742 | 19990107 <-- |
| | US 2004047848 | A1 | 20040311 | US 2003-660924 | 20030912 <-- |

Search done by Noble Jarrell

| | | | | | |
|------|-----------------|----|----------|----------------|----------|
| | US 2004191227 | A1 | 20040930 | US 2004-823263 | 20040413 |
| PRAI | US 1995-5877P | P | 19951026 | | |
| | US 1996-736413 | B1 | 19961024 | | |
| | WO 1996-US17234 | W | 19961025 | | |
| | US 1998-49757 | B1 | 19980327 | | |
| | US 1999-226742 | A1 | 19990107 | | |
| | US 2003-660924 | A1 | 20030912 | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|-------|--|
| WO 9715243 | ICM | A61F002-02 |
| | ICS | A61K009-107; A61K035-12; A61K035-39 |
| WO 9715243 | ECLA | A61K009/00M4; A61K009/50H6D; A61K035/12; A61K035/39; C12N005/06B22 |
| US 2002192190 | ECLA | A61K009/00M4; A61K009/50H6D; A61K035/12; A61K035/39; C12N005/06B22 <-- |
| US 2004047848 | ECLA | A61K009/00M4; A61K039/00D5; C12N005/06B22A; A61K009/50H6D; A61K035/39 <-- |
| US 2004191227 | ECLA | A61K009/00M4; A61K009/50H6D; A61K035/39; A61K039/00D5; C12N005/06B22A |
| AB | | A method of creating tolerance to transplanted cells, tissue, or organs without the need for continuous immunosuppression is described. An inducing tolerance dose of a cell or tissue within a membrane structure is implanted into a patient. Once the patient becomes tolerant to the cell or tissue, a tissue or organ is implanted which will no longer be recognized as foreign matter. The method makes animals organs practical for human use, prevents autoimmune destruction as well as immune rejection. It has applications in treatment and prevention of many mammalian diseases. The use of the method to induce tolerance to NIT cells in mice to allow the use of large implants to treat streptozocin-induced diabetes is demonstrate. |
| ST | | immune tolerance transplant donor cell implant |
| IT | | Animal cell line (NIT, induction of tolerance to and implantation in treatment of exptl. diabetes; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation) |
| IT | | Transplant and Transplantation (allotransplant; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation) |
| IT | | Swine (as donor, induction of immune tolerance to, in transplantation; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation) |
| IT | | Organelle (chromaffin granule, xenograft in treatment of Parkinson's disease; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation) |
| IT | | Transplant and Transplantation Transplant and Transplantation (host-vs.-graft reaction, prevention of; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation) |
| IT | | Drug delivery systems (implants, carrying cells of donor organism; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation) |
| IT | | Diabetes mellitus (induction of immune tolerance to donor organism in treatment by transplantation of; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation) |
| IT | | Cat (Felis catus) Dog (Canis familiaris) (induction of immune tolerance to donor organism in; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation) |
| IT | | Immune tolerance Transplant and Transplantation Transplant and Transplantation (induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation) |
| IT | | Pancreatic islet of Langerhans (induction of tolerance to and implantation in treatment of exptl. diabetes; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation) |
| IT | | Transplant and Transplantation (liver; induction of immunol. tolerance by habituation of host animals |

to foreign tissues for organ transplantation)

IT Encapsulation
(microencapsulation, of donor cells for implantation; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation)

IT Encapsulation
(of donor cells for implantation; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation)

IT Liver
(transplant; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation)

IT Parkinson's disease
(treatment by adrenal chromaffin granule xenograft of; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation)

IT Myasthenia gravis
(treatment by induction of immune tolerance; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation)

IT Hemophilia
(treatment by liver cell allograft of; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation)

IT Transplant and Transplantation
(xenotransplant; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation)

IT Pancreatic islet of Langerhans
(.beta.-cell, induction of tolerance to and implantation in treatment of exptl. diabetes; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation)

IT 25322-68-3, Polyethylene glycol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(encapsulation of donor tissue in, for induction of immune tolerance; induction of immunol. tolerance by habituation of host animals to foreign tissues for organ transplantation)

=> b reg

FILE 'REGISTRY' ENTERED AT 09:10:43 ON 10 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 NOV 2004 HIGHEST RN 777024-10-9
DICTIONARY FILE UPDATES: 8 NOV 2004 HIGHEST RN 777024-10-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide 13

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 25322-68-3 REGISTRY
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN .alpha.,.omega.-Hydroxypoly(ethylene oxide)
CN .alpha.-Hydro-.omega.-hydroxypoly(oxy-1,2-ethanediyl)
CN .alpha.-Hydro-.omega.-hydroxypoly(oxyethylene)
CN 1,2-Ethanediol, homopolymer
CN 16600
CN 1660S
CN 400DAB8

Search done by Noble Jarrell

CN Alkox
CN Alkox E 100
CN Alkox E 130
CN Alkox E 160
CN Alkox E 240
CN Alkox E 30
CN Alkox E 30G
CN Alkox E 45
CN Alkox E 60
CN Alkox E 75
CN Alkox R 100
CN Alkox R 1000
CN Alkox R 15
CN Alkox R 150
CN Alkox R 400
CN Alkox SR
CN Antarox E 4000
CN Aquacide III
CN Aquaaffin
CN Badimol
CN BDH 301
CN Bradsyn PEG
CN Breox 2000
CN Breox 20M
CN Breox 4000
CN Breox 550
CN Breox PEG 300
CN CAFO 154
CN Carbowax
CN Carbowax 100
CN Carbowax 1000
CN Carbowax 1350
CN Carbowax 14000
CN Carbowax 1450
CN Carbowax 1500
CN Carbowax 1540
CN Carbowax 20
CN Carbowax 200
CN Carbowax 20000
CN Carbowax 25000
CN Carbowax 300
CN Carbowax 3350
CN Carbowax 400

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

AR 9002-90-8

DR 615575-04-7, 12676-74-3, 12770-93-3, 9081-95-2, 9085-02-3, 9085-03-4,
54510-95-1, 125223-68-9, 54847-64-2, 59763-40-5, 64441-68-5, 64640-28-4,
133573-31-6, 25104-58-9, 25609-81-8, 134919-43-0, 101677-86-5, 99264-61-6,
106186-24-7, 112895-21-3, 114323-93-2, 50809-04-6, 50809-59-1,
119219-06-6, 60894-12-4, 61840-14-0, 37361-15-2, 112384-37-9, 70926-57-7,
75285-02-8, 75285-03-9, 77986-38-0, 150872-82-5, 154394-38-4, 79964-26-4,
80341-53-3, 85399-22-0, 85945-29-5, 90597-70-9, 88077-80-9, 88747-22-2,
34802-42-1, 107502-63-6, 107529-96-4, 116549-90-7, 156948-19-5,
169046-53-1, 188364-77-4, 188924-03-0, 189154-62-9, 191743-71-2,
201163-43-1, 206357-86-0, 221638-71-7, 225502-44-3, 270910-26-4,
307928-07-0, 356055-70-4, 391229-98-4

MF (C2 H4 O)n H2 O

CI PMS, COM

PCT Polyether

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*,
DIOGENES, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2,
HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC,
PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN,
USPAT2, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA Caplus document type: Book; Conference; Dissertation; Journal; Patent;
Preprint; Report

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC
(Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process);
PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role)


Search done by Noble Jarrell

in record)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)



79152 REFERENCES IN FILE CA (1907 TO DATE)
 21488 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 79330 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b wpix

FILE 'WPIX' ENTERED AT 09:10:55 ON 10 NOV 2004
 COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE LAST UPDATED: 9 NOV 2004 <20041109/UP>
 MOST RECENT DERWENT UPDATE: 200472 <200472/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
 GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
 DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
 FIRST VIEW - FILE WPIFV.
 FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> NEW DISPLAY FORMAT HITSTR ADDED ALLOWING DISPLAY OF
 HIT STRUCTURES WITHIN THE BIBLIOGRAPHIC DOCUMENT <<<

>>> SMILES and ISOSMILES strings are no longer available as
 Derwent Chemistry Resource display fields <<<

=> d all 14

L4 ANSWER 1 OF 1 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN
 AN 1997-258713 [23] WPIX
 DNN N1997-213975 DNC C1997-083532
 TI Induction of immunological tolerance - by implanting foreign cells or
 tissue in permselective membrane prior to implantation of foreign cells,
 tissues or organs.
 DC A96 B04 D22 P32
 IN LATTA, P P
 PA (LATT-I) LATTA P P
 CYC 75
 PI WO 9715243 A1 19970501 (199723)* EN 27 A61F002-02
 RW: AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD
 SE SZ UG
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
 HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX
 NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

Search done by Noble Jarrell

AU 9674795 A 19970515 (199736) A61F002-02
 EP 955948 A1 19991117 (199953) EN A61F002-02
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 US 2002192190 A1 20021219 (200303) A61K038-28 <--
 US 2004047848 A1 20040311 (200419) A61K048-00 <--
 US 2004191227 A1 20040930 (200465) A61K045-00
 ADT WO 9715243 A1 WO 1996-US17234 19961025; AU 9674795 A AU 1996-74795
 19961025; EP 955948 A1 EP 1996-937029 19961025, WO 1996-US17234 19961025;
 US 2002192190 A1 Provisional US 1995-5877P 19951026, Cont of US
 1996-736413 19961024, Cont of US 1998-49757 19980327, US 1999-226742
 19990107; US 2004047848 A1 Provisional US 1995-5877P 19951026, Cont of US
 1996-736413 19961024, Cont of US 1998-49757 19980327, Cont of US
 1999-226742 19990107, US 2003-660924 20030912; US 2004191227 A1
 Provisional US 1995-5877P 19951026, Cont of US 1996-736413 19961024, Cont
 of US 1998-49757 19980327, Cont of US 1999-226742 19990107, Cont of US
 2003-660924 20030912, US 2004-823263 20040413
 FDT AU 9674795 A Based on WO 9715243; EP 955948 A1 Based on WO 9715243
 PRAI US 1995-5877P 19951026; US 1996-736413 19961024;
 US 1998-49757 19980327; US 1999-226742 19990107;
 US 2003-660924 20030912; US 2004-823263 20040413
 REP 5.Jnl.Ref
 IC ICM A61F002-02; A61K038-28; A61K045-00; A61K048-00
 ICS A01N063-00; A01N065-00; A61F002-00; A61K009-107; A61K009-14;
 A61K009-48; A61K035-12; A61K035-39; A61K039-00; A61K039-38;
 C07K016-28; C12N001-00; C12N005-00; C12N005-02
 AB WO 9715243 A UPAB: 19970606
 Creating immunological tolerance to foreign cells, tissues or organs in a
 mammal comprises implanting in the mammal a tolerising dose of foreign
 cells or tissue corresponding to the foreign cells, tissues or organs
 which shed antigens contained in or on the foreign cells, tissues or
 organs, the corresponding foreign cells or tissue being encapsulated in a
 biologically permselective membrane. Also claimed is the use of a
 tolerising dose of foreign cells or tissue encapsulated in a biologically
 compatible permselective membrane in the preparation of a medicament for
 creating immunological tolerance to foreign cells, tissues or organs in a
 mammal.
 USE - The method can be used for organ transplantation, e.g. heart or
 liver transplant or for the treatment of diseases, using e.g.
 insulin-secreting islet cells for Type I diabetes, Factor VIII-secreting
 hepatic cells for haemophilia, dopamine-secreting adrenal chromaffin cells
 for Parkinson's disease and collagen for arthritis. The method can also be
 used for the treatment of e.g. hypoparathyroidism (thyroid hormone),
 hyperadrenocorticalism (adrenocorticotrophic factor), dwarfism (growth
 hormone), Gaucher's disease (glucocerebrosidase), Tay-Sachs
 (hexosaminidase A) cystic fibrosis (cystic fibrosis transmembrane
 regulator), amyotrophic lateral sclerosis, Alzheimer's disease,
 Huntington's Chorea, epilepsy, hepatitis, anxiety, stress, pain,
 addiction, obesity, menopause, endometriosis, osteoporosis,
 hypercholesterolaemia, hypertension and allergies. The method can also be
 used for the treatment of diabetes, arthritis, multiple sclerosis,
 myasthenia gravis and systemic lupus erythematosus by replacing destroyed
 tissue or organs.
 ADVANTAGE - Using the permselective membrane, the immune system will
 begin to become tolerant to the shed antigens because they do no actual
 damage in the body and the constant source cannot be destroyed. At this
 time the immune system is tolerant to that particular cell type from that
 particular donor. Subsequently, implanted cells, tissues or organs are not
 rejected.
 Dwg.0/7
 FS CPI GMPI
 FA AB
 MC CPI: A12-V02; B04-F02; B11-C04A; B14-D02; B14-J01A4; B14-J07; B14-M01;
 B14-S01; D09-C01C

=> b home

FILE 'HOME' ENTERED AT 09:11:05 ON 10 NOV 2004

=>